A Study of AMDX-2011P in Participants With Alzheimer's Disease

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Amydis Inc.
Study ID
NCT06514001
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • AMDX-2011P — DRUG
    AMDX-2011P single bolus injection intravenous for diagnostic review

Study Details

The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).

Key Dates

Start date
Mar 7, 2025
Status verified
Feb 2026
Primary completion
Sep 30, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: AMDX-2011P 100 milligram
    AMDX2011P 100 milligram (4 milliliter) single bolus injection intravenous for diagnostic review

Primary Outcome Measure

AMDX-2011P Adverse Events Profile [ Time Frame: 8 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Associated Retina ConsultantsPhoenixArizona85020
Mallory Mintert
[email protected]

Find similar trials in Phoenix, AZ

By condition
Alzheimer's disease
By specialty
NeurologyDementia careBrain disordersGeriatrics
By research site
Associated Retina Consultants· Phoenix, AZ

Related Studies